The prevalence of asymptomatic chlamydial and gonococcal infections in male and female military populations was determined using urine-based ligase chain reaction DNA amplification assays (DAAs). Cross-sectional surveys in four military settings revealed an overall prevalence of asymptomatic chlamydial infection of 4.2% (56/1338). This included 3.4% (21/618) of Western Pacific shipboard US Marine Corps enlisted men; 5.2% (21/406) of male marines shore-based in Okinawa, Japan; 2.7% (5/183) of female enlisted US Navy subtender personnel in dry dock; and 6.9% (9/131) of shore-based female naval personnel in San Diego. No gonococcal infections were detected. All subjects were treated within 2 weeks of screening; none of them had progressed to symptomatic disease. General population-based screening for asymptomatic sexually transmitted diseases, and in particular chlamydial infection, can be successfully implemented using urine-based DAA tests. Benefits are maximized in a population in which compliance for follow-up therapy is high.
Sexually transmitted diseases (STDs) continue to be a highA new era in chlamydial detection and control has emerged with the recent licensure of the DNA amplification assays source of morbidity and costs for young adults [1]. Chlamydia trachomatis is the most common bacterial STD in the United (DAAs), ligase chain reaction (LCR) and polymerase chain reaction (PCR). The sensitivity (90% -99%), specificity (99% -States, with an estimated 4 million infections occurring annually, costing several billion dollars [2]. Morbidity is especially 100%), and positive predictive value of these assays are very high when applied to genital specimens. The sensitivity is high in women; sequelae include pelvic inflammatory disease, infertility, ectopic pregnancy, and the potential for neonatal greater than the previous reference standard of tissue culture. Importantly, the performance of DAAs to detect Chlamydia transmission [3]. The introduction of noninvasive Chlamydia antigen detection tests, such as EIAs of urine, represented a organisms and gonorrhea in the urine of both women and men (88% -96% sensitivity) is similar to the performance of these major advance for the detection of symptomatic and asymptomatic infection in men [4]. However, the sensitivity of these assays on urethral and endocervical swabs from symptomatic and asymptomatic women and men [2, 5, 6]. The DAAs permit, assays in the urine of infected women is suboptimal, ranging from 35% to 40%, and requires an endocervical swab for EIA for the first time, accurate documentation of asymptomatic chlamydial and gonococcal infection rates in various populascreening and diagnosis [5].tion groups with an easily applied noninvasive urine test. In addition, serial PCR sampling following antibiotic therapy doc-